{"url_path":"/sec/tgtx/8-k/2026-02-26/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-02-26","source_url":"https://www.sec.gov/Archives/edgar/data/1001316/0001437749-26-005733-index.html","accession_number":"0001437749-26-005733","cik":"0001001316","ticker":"TGTX","issuer_name":"TG THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1001316/0001437749-26-005733-index.html","primary_entity_key":"0001001316","primary_entity_name":"TG THERAPEUTICS, INC."},"word_count":143,"has_tables":true,"body_markdown":"**Item 2.02. Results of Operations and Financial Condition.**\n\n ​\n\nOn February 26, 2026, the Company issued a press release announcing results of operations for the three and twelve months ended December 31, 2025. A copy of such press release is being furnished as Exhibit 99.1.\n\n \n\nIn accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing."}